secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001104659-24-074763
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST
-------------------------------------------------------------------------

- Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.
- Kiniksa committed to purchase PPQ and pre-approval inspection batches; additional batches required in 2027-2031.
- PSA continues until later of Dec 31, 2031 or service completion; MSA initial 10-year term with 2-year auto-renewals.
- Agreement includes customary indemnification, IP protection, limitation of liability, and confidentiality provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924074763/0001104659-24-074763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924074763/tm2417478d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-074763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer